Literature DB >> 18929323

U-waves and T-wave peak to T-wave end intervals in patients with catecholaminergic polymorphic ventricular tachycardia, effects of beta-blockers.

Matti Viitasalo1, Lasse Oikarinen, Heikki Väänänen, Kimmo Kontula, Lauri Toivonen, Heikki Swan.   

Abstract

BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by risk of polymorphic ventricular tachycardia (pVT) and sudden death during stress. Experimental CPVT models show that delayed afterdepolarization (DAD)-induced triggered activity is the initiating mechanism of pVT, whereas an increase in transmural dispersion of repolarization (TDR) controls degeneration of pVT to ventricular fibrillation. U-wave and T-wave peak to T-wave end interval (TPE) are regarded as electrocardiographic counterparts of DAD and TDR, respectively.
OBJECTIVE: We tested hypotheses that patients with CPVT might show abnormal U-waves and TPE intervals and that beta-blockers could suppress appearance of these repolarization abnormalities.
METHODS: We reviewed Holter recordings from 19 CPVT patients with a RyR2 mutation (P2328S or V4653F) and from 19 healthy unaffected subjects to record U-waves and TPE intervals as well as to measure beta-blockers' effects on ventricular repolarization by use of an automated computerized program.
RESULTS: The maximal U-wave to T-wave amplitude ratio was 0.8 +/- 0.6 in CPVT patients and 0.4 +/- 0.3 in unaffected subjects (P = .009). Patients with most ventricular extrasystoles had a higher U-wave to T-wave amplitude ratio than those with fewest extrasystoles. Treatment with beta-blockers decreased U-wave amplitude at high heart rates. CPVT patients had longer TPE intervals than unaffected subjects at high heart rates, and beta-blocker treatment shortened their TPE intervals.
CONCLUSION: Present data support the hypothesis that U-waves associate with the DAD-triggered extrasystolic activity in CPVT patients. Patients with a RyR2 mutation show increased TPE at high heart rates. Beta-blocker treatment suppresses observed repolarization abnormalities in CPVT patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929323     DOI: 10.1016/j.hrthm.2008.06.011

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  10 in total

1.  Behavior of the electrocardiographic T peak to end interval in childhood.

Authors:  Abraham Benatar; Karlien Carbonez
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-01       Impact factor: 1.468

2.  Impact of Iron and Homocysteine Levels on T Peak-to-End Interval and Tp-e/QT Ratio in Elite Athletes.

Authors:  Serkan Duyuler; Pınar Türker Duyuler; Mustafa Kemal Batur
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-28       Impact factor: 1.468

3.  Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.

Authors:  Eyal Nof; Bernard Belhassen; Michael Arad; Zahurul A Bhuiyan; Charles Antzelevitch; Raphael Rosso; Rami Fogelman; David Luria; Dalia El-Ani; Marcel M A M Mannens; Sami Viskin; Michael Eldar; Arthur A M Wilde; Michael Glikson
Journal:  Heart Rhythm       Date:  2011-05-26       Impact factor: 6.343

4.  Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.

Authors:  Mette Nyegaard; Michael T Overgaard; Mads T Søndergaard; Marta Vranas; Elijah R Behr; Lasse L Hildebrandt; Jacob Lund; Paula L Hedley; A John Camm; Göran Wettrell; Inger Fosdal; Michael Christiansen; Anders D Børglum
Journal:  Am J Hum Genet       Date:  2012-10-05       Impact factor: 11.025

5.  Tpeak -tend interval in 12-lead electrocardiogram of healthy children and adolescents tpeak -tend interval in childhood.

Authors:  Katarzyna Bieganowska; Małgorzata Sawicka-Parobczyk; Maciej Bieganowski; Jarosław Piskorski
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

6.  Accelerated junctional rhythm and nonalternans repolarization lability precede ventricular tachycardia in Casq2-/- mice.

Authors:  Ure L Mezu; Prabhpreet Singh; Vladimir Shusterman; Hyun-Seok Hwang; Bjorn C Knollmann; Jan Němec
Journal:  J Cardiovasc Electrophysiol       Date:  2012-08-02

Review 7.  Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Tommy Dharmawan; Tadashi Nakajima; Seiko Ohno; Takashi Iizuka; Shuntaro Tamura; Yoshiaki Kaneko; Minoru Horie; Masahiko Kurabayashi
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-01-07       Impact factor: 1.468

8.  Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.

Authors:  Kirsi Kujala; Jere Paavola; Anna Lahti; Kim Larsson; Mari Pekkanen-Mattila; Matti Viitasalo; Annukka M Lahtinen; Lauri Toivonen; Kimmo Kontula; Heikki Swan; Mika Laine; Olli Silvennoinen; Katriina Aalto-Setälä
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

9.  T-peak to T-end abnormality in pediatric patients with syncope.

Authors:  Hamid Amoozgar; Mohammad Hosseiniasl
Journal:  Iran J Pediatr       Date:  2012-09       Impact factor: 0.364

10.  R4496C RyR2 mutation impairs atrial and ventricular contractility.

Authors:  Cecilia Ferrantini; Raffaele Coppini; Beatrice Scellini; Claudia Ferrara; Josè Manuel Pioner; Luca Mazzoni; Silvia Priori; Elisabetta Cerbai; Chiara Tesi; Corrado Poggesi
Journal:  J Gen Physiol       Date:  2015-12-14       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.